EU Investigates Sanofi's Flu Vaccine Campaign

The European Commission has launched an investigation into Sanofi's marketing practices surrounding its flu vaccine 'Efluelda'. The Commission suspects Sanofi of conducting a misleading campaign against a competitor's product in France and Germany. Sanofi holds a dominant market position in these regions.

The European Commission has initiated an investigation regarding the marketing strategies employed by French pharmaceutical giant Sanofi. The inquiry focuses on whether Sanofi violated EU competition laws in promoting its flu vaccine 'Efluelda'.

The commission expressed concerns over Sanofi's potentially misleading marketing efforts in France and Germany, aimed at undermining the rival flu vaccine 'Fluad', manufactured by CSL Seqirus. According to the commission, Sanofi holds a considerable market dominance in these countries.

A spokesperson for Sanofi assured full cooperation with the European Commission, emphasizing the company's commitment to complying with all relevant laws, including competition regulations. The investigation follows unannounced raids on Sanofi's offices conducted in September 2025.